Updated Phase 1 Data Show Bavarian Nordic´s Vaccine Candidate Induces a Broad and Durable Immune Response against RSV
(WorldNews Denmark)

Antibody levels maintained against multiple targets 6 months post vaccination Additional T cell data confirms broad activity against all 5 RSV targets included in the vaccine COPENHAGEN, Denmark, February 23, 2017 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced 6 month follow-up data from the Phase 1 trial of MVA-BN RSV, its novel, broad spectrum vaccine against respiratory syncytial virus (RSV). The randomized, placebo-controlled trial, evaluated the safety, tolerability and immunogenicity of the recombinant vaccine in 63 healthy adults, including an elderly group of individuals and positive top line results were reported in May 2016. The 6 month (30 weeks) analysis revealed...